Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

LigaChem Doses First Patient in Global Trial of Cancer-Targeting ADC

LigaChem Biosciences has begun global clinical development of its proprietary Claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC) candidate, LCB02A. The company announced on Oct.

  • LigaChem begins global Phase 1/2 trial for CLDN18.2-targeting ADC LCB02A on October 15
  • Study involves up to 191 patients with advanced solid tumors expressing CLDN18.2
  • ADC uses LigaChem's ConjuAll platform with exatecan cytotoxic payload

More from Friday 16 October →